Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Bioxcel Therapeutics ( (BTAI) ) has provided an announcement.
On May 27, 2025, BioXcel Therapeutics announced that it received an extension from the Nasdaq Hearings Panel to regain compliance with Nasdaq Listing Rule 5550(b)(2) until September 16, 2025. This extension allows the company additional time to meet the requirement of maintaining a market value of listed securities of at least $35 million for 10 consecutive business days, which is crucial for its continued listing on the Nasdaq Stock Market.
The most recent analyst rating on (BTAI) stock is a Buy with a $112.00 price target. To see the full list of analyst forecasts on Bioxcel Therapeutics stock, see the BTAI Stock Forecast page.
Spark’s Take on BTAI Stock
According to Spark, TipRanks’ AI Analyst, BTAI is a Underperform.
Bioxcel Therapeutics’ stock is rated at the lowest end of the scale due to substantial financial instability, including ongoing losses, high debt, and negative cash flows. Short-term technical indicators and valuation metrics further highlight the current challenges. The company needs to address these financial and operational issues to improve its stock performance.
To see Spark’s full report on BTAI stock, click here.
More about Bioxcel Therapeutics
BioXcel Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on the development of innovative medicines for neurological and immuno-oncology disorders.
Average Trading Volume: 4,666,190
Technical Sentiment Signal: Sell
Current Market Cap: $8.42M
See more insights into BTAI stock on TipRanks’ Stock Analysis page.